23andMe Holding Co.
349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 560
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Ms. Anne Wojcicki | Co-Founder, CEO, President & Chair of the Board | 62.92k | 無 | 無 |
| Mr. Joseph Selsavage | Chief Financial & Accounting Officer | 574.56k | 無 | 1964 |
| Mr. Eli Fry | Vice President of Operations | 無 | 無 | 無 |
| Mr. Guy Chayoun | VP, Interim General Counsel & Corporate Secretary | 無 | 無 | 無 |
| Ms. Katie Watson | Vice President of Communications | 無 | 無 | 1978 |
| Mr. Jonathan Ward | Chief Marketing Officer | 無 | 無 | 無 |
| Mr. Reza Afkhami M.B.A. | Chief Corporate Development Officer | 無 | 無 | 無 |
| Ms. Savita Pillai | Vice President of People | 無 | 無 | 無 |
| Dr. Jennifer Low M.D., Ph.D. | Head of Therapeutics Development | 無 | 無 | 1969 |
| Mr. Kent Hillyer | Vice President of Consumer Operations | 無 | 無 | 1968 |
描述
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.
公司管治
截至 2024年6月1日 止，23andMe Holding Co. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：3；董事會：8；股東權利：10；現金賠償：8。
